Welcome to the Braddock Lab

We study the pathophysiology of benign and malignant hematologic disorders using biochemical and biophysical methods. Recently, we uncovered two endothelial bound enzymes on the cerebral vasculature that induce platelet aggregation via the hydrolysis of a small molecule released by platelets upon degranulation. We have proposed that these enzymes are unrecognized factors capable of inducing central hemostasis/stroke, a hypothesis supported by recent genomic studies revealing genes conferring stroke protection to patients at risk for thrombotic stroke (see press release).

Inozyme Pharmaceuticals aims to develop a therapy for an ultra-rare infant disorder—this is based on the work of Yale University pathologist Demetrios Braddock.

Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders

Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease

$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come